Reply to: Comments on “Adverse reactions associated with immune checkpoint inhibitors and bevacizumab: A pharmacovigilance analysis”
International Journal of Cancer · 2023
DOI: 10.1002/ijc.34497 ↗Kurz gefasst
Leserbrief in der Zeitschrift International Journal of Cancer, 2023. Verfasst von Tianqi Gu und 4 weiteren Autor:innen. Beteiligte Einrichtung: Department of Oncology, Zhujiang Hospital, Southern Medical University, Guangzhou, Guangdong, China. Hauptthemen laut MEDLINE: Antineoplastic Agents, Immunological, Drug-Related Side Effects and Adverse Reactions. Die Arbeit nennt 9 Literaturangaben.
Abstract (Originalsprache)
The data that support the findings of our study are available from the corresponding author upon reasonable request.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Department of Oncology, Zhujiang Hospital, Southern Medical University, Guangzhou, Guangdong, China.
- Thoracic Surgery Branch, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, Maryland, USA.
ORCID-Profile: Peng Luo
Zitieren
APA
Gu, T., Lin, A., Wang, H., Zhang, J., & Luo, P. (2023). Reply to: Comments on “Adverse reactions associated with immune checkpoint inhibitors and bevacizumab: A pharmacovigilance analysis”. International Journal of Cancer. https://doi.org/10.1002/ijc.34497
Vancouver
Gu T, Lin A, Wang H, Zhang J, Luo P. Reply to: Comments on “Adverse reactions associated with immune checkpoint inhibitors and bevacizumab: A pharmacovigilance analysis”. International Journal of Cancer. 2023. doi:10.1002/ijc.34497
BibTeX
@article{Gu2023,
author = {Gu, Tianqi and Lin, Anqi and Wang, Haitao and Zhang, Jian and Luo, Peng},
title = {Reply to: Comments on “Adverse reactions associated with immune checkpoint inhibitors and bevacizumab: A pharmacovigilance analysis”},
journal = {International Journal of Cancer},
year = {2023},
doi = {10.1002/ijc.34497}
}
EUVIMED